Intravenous prostanoids in systemic sclerosis-associated pulmonary arterial hypertension: a single-centre experience.

Objectives: The current study evaluates survival rates among SSc-associated pulmonary arterial hypertension (SSc-PAH) patients on i.v. prostanoids, and short-term impact of i.

Ambulatory prostanoid therapy: safe reduction in duration of inpatient training.

Aims: IV prostanoid therapy for advanced pulmonary arterial hypertension requires lifelong, continuous infusion, and extensive self-care. The inpatient training pathway (ITP) ensures patient competency but can be psychologically and physically demanding. Therefore, an alternative Elective Prostanoid Admission Pathway (EPAP) was developed.